Related Experiment Video
Updated: Jun 13, 2026
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Gene expression profiling predicts response to temozolomide in malignant gliomas
Atsuo Yoshino1, Akiyoshi Ogino, Kazunari Yachi
1Department of Neurological Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan. ayoshino@med.nihon-u.ac.jp
International Journal of Oncology
|April 30, 2010
Summary
Understanding temozolomide (TMZ) resistance in malignant gliomas is crucial for improving treatment. This study identified genes associated with TMZ sensitivity, offering potential biomarkers and therapeutic targets for overcoming drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Temozolomide (TMZ) is a standard chemotherapy agent, but resistance limits its efficacy.
- Improved understanding of TMZ resistance mechanisms is needed to enhance treatment outcomes.
Purpose of the Study:
- To identify genes predicting malignant glioma response to temozolomide (TMZ).
- To explore molecular markers for TMZ sensitivity and resistance.
- To lay the groundwork for novel therapeutic strategies against TMZ-resistant gliomas.
Main Methods:
- Assessed in vitro TMZ response (IC50 values) in seven malignant glioma cell lines.
- Utilized cDNA microarray to analyze gene expression profiles.
- Correlated gene expression with TMZ sensitivity to identify key genes.
- Confirmed MGMT methylation status, mRNA, and protein levels in resistant cells.
Main Results:
- Identified several up-regulated and down-regulated genes associated with TMZ sensitivity/resistance.
- MGMT (O-6-methylguanine-DNA methyltransferase) was confirmed as a key factor in TMZ response.
- Gene expression patterns correlated with TMZ sensitivity in glioma cell lines.
- MGMT methylation, mRNA, and protein levels were validated in TMZ-resistant cells.
Conclusions:
- Candidate genes identified may serve as molecular markers for TMZ sensitivity/resistance.
- These genes could represent novel therapeutic targets for overcoming TMZ resistance.
- Findings support the existence of dominant mechanisms of TMZ resistance in gliomas.
- The study provides a basis for developing new combination therapies to improve glioma treatment.
